Jun 18, 2020
Nephrologists Are Hesitant to Fully Embrace Janssen's INVOKANA Despite Being the First and Only SGLT2 Inhibitor with an FDA Indication to Treat Diabetic Kidney Disease
May 05, 2020
FDA approves new treatment for a type of heart failure
Jun 11, 2019
Canagliflozin Shown to Improve Cardiovascular and Renal Outcomes in People with Type 2 Diabetes and Kidney Disease
Nov 10, 2018
Forxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark DECLARE-TIMI 58 trial
Oct 04, 2018
Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
Jun 25, 2018
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
Jun 23, 2018
Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors
May 24, 2018
New Review of the Real-world Data on the Cardiovascular Benefits Associated with the Use of Sodium-glucose Cotransporter 2 Inhibitors - touchENDOCRINOLOGY
Jan 02, 2018
Lawsuits Filed Against J&J Related to its Drug Invokana
Nov 17, 2017
New Real-World Analysis Shows INVOKANA® (canagliflozin) and Other SGLT2 Inhibitors Reduced the Risk of Death and Cardiovascular Events Compared to Other Diabetes Medicines
Sep 12, 2017
Jardiance® (empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control
Jun 12, 2017
Jardiance® (empagliflozin) tablets to be studied in chronic kidney disease